Iterum Therapeutics plc (NASDAQ:ITRM) and BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Iterum Therapeutics plc||N/A||78.68||61.92M||-4.59||0.00|
|BiondVax Pharmaceuticals Ltd.||N/A||0.00||N/A||-2.30||0.00|
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 shows Iterum Therapeutics plc and BiondVax Pharmaceuticals Ltd.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Iterum Therapeutics plc||0.00%||0%||0%|
|BiondVax Pharmaceuticals Ltd.||0.00%||0%||0%|
Institutional & Insider Ownership
The shares of both Iterum Therapeutics plc and BiondVax Pharmaceuticals Ltd. are owned by institutional investors at 76.8% and 0% respectively. About 1.2% of Iterum Therapeutics plc’s share are held by insiders. Competitively, insiders own roughly 22.93% of BiondVax Pharmaceuticals Ltd.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Iterum Therapeutics plc||-1.36%||-11.64%||-16.41%||-47.84%||0%||8.28%|
|BiondVax Pharmaceuticals Ltd.||-2.76%||-3.81%||-16.86%||-11.17%||-19.57%||3.36%|
For the past year Iterum Therapeutics plc has stronger performance than BiondVax Pharmaceuticals Ltd.
On 3 of the 5 factors Iterum Therapeutics plc beats BiondVax Pharmaceuticals Ltd.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate includes M-001, a synthetic peptide-based protein, which is in Phase II clinical development stage targeting seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is based in Ness Ziona, Israel.